Drug Search Results
More Filters [+]

GBC-R1

Alternative Names: GBC-R1
Latest Update: 2023-08-08
Latest Update Note: Clinical Trial Update

Product Description

GBC-R1 is an immunomodulatory protein identified from a gastric bacterium that protects against allergic asthma, hay fever, atopic dermatitis, inflammatory bowel disease, as well as other allergic diseases. (Sourced from: http://genevabiotechcenter.com/wp-content/uploads/2017/10/GBC-HpVac-Investor-Leaflet-October-2017.pdf)

Mechanisms of Action: Immunomodulator

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Geneva Biotech Center
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GBC-R1

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Asthma, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title